Advertisement

Topics

ASCO 2017 – Lung Cancer – Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC

19:56 EDT 16 Aug 2017 | GRACE

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?

Original Article: ASCO 2017 – Lung Cancer – Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC

NEXT ARTICLE

More From BioPortfolio on "ASCO 2017 – Lung Cancer – Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...